Trump Medicare drug pricing model may hit only four firms after exemptions

• More than two dozen drugmakers, including Pfizer, Eli Lilly, and Novo Nordisk, are exempt from the GLOBE pricing model due to separate White House deals
• Projected Medicare Part B savings collapsed by 96% from the proposed rule's $11.9 billion estimate to just $440 million in the final rule
• The White House claims its broader drug pricing agreements could save state and federal governments $64.2 billion combined over the next decade

Summary

The Trump administration's Medicare drug pricing model, called GLOBE, will impact significantly fewer pharmaceutical companies than initially anticipated after granting exemptions to manufacturers with separate pricing agreements.

Key Developments:

The finalized rule, published October 1st, exempts companies that signed "most favored nation" pricing deals with the White House. As a result, only four unnamed drugmakers will be subject to the GLOBE price-setting model, according to a footnote in the regulation.

Dramatic Cost Reduction:

The Department of Health and Human Services sharply reduced projected savings estimates:

• New projection: $440 million in Medicare Part B savings over the model period
• Original projection: $11.9 billion
• Reduction: approximately 96% decrease in expected savings

HHS did not provide explanation for this substantial downward revision.

Exempted Companies:

More than two dozen drugmakers have signed separate pricing agreements with the administration, including major pharmaceutical companies:

• Pfizer
• Eli Lilly
• Novo Nordisk

Broader Implications:

According to the White House Council of Economic Advisers, the overall drug pricing initiative could generate:

• $27.6 billion in savings for state governments
• $36.6 billion in federal savings
• Time frame: over the next decade

Market Impact:

The significantly reduced scope and projected savings of the GLOBE model may disappoint investors hoping for broader Medicare drug pricing reform. The exemption of major pharmaceutical companies suggests limited near-term pricing pressure on the industry's largest players, potentially providing relief to pharmaceutical sector stocks.